Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19

Aakriti Gupta (), Mahesh V. Madhavan, Timothy J. Poterucha, Ersilia M. DeFilippis, Jessica A. Hennessey, Bjorn Redfors, Christina Eckhardt, Behnood Bikdeli, Jonathan Platt, Ani Nalbandian, Pierre Elias, Matthew J. Cummings, Shayan N. Nouri, Matthew Lawlor, Lauren S. Ranard, Jianhua Li, Claudia Boyle, Raymond Givens, Daniel Brodie, Harlan M. Krumholz, Gregg W. Stone, Sanjum S. Sethi, Daniel Burkhoff, Nir Uriel, Allan Schwartz, Martin B. Leon, Ajay J. Kirtane, Elaine Y. Wan () and Sahil A. Parikh
Additional contact information
Aakriti Gupta: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Mahesh V. Madhavan: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Timothy J. Poterucha: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Ersilia M. DeFilippis: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Jessica A. Hennessey: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Bjorn Redfors: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Christina Eckhardt: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Behnood Bikdeli: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Jonathan Platt: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Ani Nalbandian: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Pierre Elias: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Matthew J. Cummings: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Shayan N. Nouri: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Matthew Lawlor: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Lauren S. Ranard: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Jianhua Li: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Claudia Boyle: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Raymond Givens: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Daniel Brodie: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Harlan M. Krumholz: Yale Center for Outcomes Research and Evaluation
Gregg W. Stone: Cardiovascular Research Foundation
Sanjum S. Sethi: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Daniel Burkhoff: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Nir Uriel: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Allan Schwartz: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Martin B. Leon: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Ajay J. Kirtane: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Elaine Y. Wan: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center
Sahil A. Parikh: NewYork-Presbyterian Hospital and the Columbia University Irving Medical Center

Nature Communications, 2021, vol. 12, issue 1, 1-9

Abstract: Abstract The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, p

Date: 2021
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-021-21553-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:12:y:2021:i:1:d:10.1038_s41467-021-21553-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-021-21553-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().